Miist Therapeutics provides a vibration‑driven, breath‑actuated inhaler that generates sterile aqueous particles half the size of conventional aerosols, enabling peripheral lung deposition and systemic drug delivery within seconds. The platform delivers rapid‑onset therapies for acute conditions such as nicotine cravings and migraine, and includes programmable dose tapering for sustained treatment.
Funding
Funding not disclosed
Founders
Product
Problem
Current inhalation devices generate particles that deposit primarily in the central lung, resulting in slow systemic absorption and delayed therapeutic effect. Acute conditions such as nicotine cravings or migraine attacks require drug action within minutes, but existing oral or inhaled treatments often take 30 minutes to hours to reach effective plasma levels.
Solution
Miist Therapeutics has engineered a vibration‑driven inhaler that creates sterile aqueous particles approximately 50 % smaller than those from conventional devices. The reduced particle size enables deposition in the peripheral lung, whose ultra‑thin alveolar barrier allows drugs to enter the bloodstream within seconds, achieving peak plasma concentrations in under 30 seconds. This rapid pharmacokinetic profile supports the development of fast‑acting therapies for acute indications, exemplified by a smoking‑cessation formulation that eliminates cravings in two minutes and a migraine candidate targeting relief within five minutes. The platform also incorporates programmable dose tapering to address underlying disease mechanisms while maintaining the convenience of a single breath actuation.
Target Audience
The primary customers are pharmaceutical developers and clinical teams seeking rapid‑onset treatments for acute conditions such as nicotine dependence, migraine, and other time‑critical disorders.
Features
- Vibration‑based aerosol generator producing sterile aqueous particles 50 % smaller than standard inhalers, ensuring peripheral lung deposition
- Peripheral lung delivery route that yields systemic drug levels comparable to intravenous administration in <30 seconds
- Breath‑actuated, single‑use inhaler design for instant, on‑the‑spot administration without additional equipment
- Integrated programmable dosing algorithm that automatically reduces dose by ~1 % per day over a 12‑week course to support receptor down‑regulation
- Closed‑system particle formation eliminates heat exposure, preserving drug stability and enhancing safety
- Scalable platform compatible with a broad range of small‑molecule and peptide therapeutics for acute care indications